8-K filing — Opus Genetics, Inc. (IRD)
Filed: 2026-09-11 AccNo: 0001140361-26-036277 Size: 7 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Oppenheimer Maintains Outperform on Opus Genetics, Raises Price Target to $20
Oppenheimer analyst Andreas Argyrides maintains Opus Genetics (NASDAQ:IRD) with a Outperform and raises the price target from $10 to $20.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Wedbush Maintains Outperform on Opus Genetics, Raises Price Target to $13
Wedbush analyst Yun Zhong maintains Opus Genetics (NASDAQ:IRD) with a Outperform and raises the price target from $10 to $13.
HC Wainwright & Co. Reiterates Buy on Opus Genetics, Maintains $8 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Opus Genetics (NASDAQ:IRD) with a Buy and maintains $8 price target.